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Abstract
Background The incidence of colorectal cancer rises
disproportionally in aging persons. With a shift towards
higher population age in general, an increasing number of
older patients require adequate treatment. This study aims to
investigate differences between young and elderly patients
who undergo resection for colorectal cancer, regarding clinical
characteristics, morbidity, and prognosis.
Methods By retrospective analysis of 6 years (2007 to 2012)
of a prospectively documented database, a total of 636 pa-
tients were identified who underwent oncological resection
for colorectal cancer at our institution. Of this total, all 569
patients with primary colorectal adenocarcinoma were includ-
ed. Four hundred ten patients were 74 years or younger and
159 were 75 years or older. The median follow-up was
22 months.
Results Older patients had significantly more comorbidities
(85 % vs. 56%, p<0.001) and a higher ASA score (p<0.001).
The mean length of stay in the hospital was longer (24 vs.
20 days, p=0.002), as was the length of postoperative inten-
sive care stay (4 vs. 2 days, p=0.003). However, elderly
patients did not have significantly higher rates of intraopera-
tive complications or surgical morbidity. Tumor-specific 2-
year survival was 83±4 % for the elderly and 87±2 % for the
younger patients, which was not significantly different (p=
0.90).
Conclusions Long-term outcome after oncologic resection for
colorectal cancer does not differ between elderly and younger
patients. Age in general should not be considered as a limiting
factor for colorectal cancer surgery or tumor-specific
prognosis.
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Introduction
With a rise from 5 to 14 %, the percentage of people over
80 years is estimated to be more than doubled in 2050 in
Western countries [1–3]. Aging may alter the body’s anti-
tumor defenses, making older persons more vulnerable to
malignancies [4, 5]. The three main cancer entities whose
incidence rates are rising most with advancing population
age are prostate, lung, and colorectal cancers [4]. A contin-
uously increasing number of elderly patients with colorectal
cancer is seeking treatment, and medical as well as surgical
options are improving. Personalized treatment regimens in-
clude different neoadjuvant concepts for rectal cancer, lim-
ited palliative versus advanced oncological tumor resec-
tions, and combinations of chemotherapeutic agents and
targeted therapies [6].
Distinct guidelines exist regarding the age of admission to
screening programs and stage dependent treatment of colorec-
tal cancer [6–8]. However, in contrast to screening, age is not
reflected in treatment specifications [6–8]. Indications or con-
traindication for neoadjuvant treatment and surgery depending
on patient age are not defined in current guidelines at all [7].
Age per se is no contraindication for adjuvant treatment [7],
nevertheless, elderly patients are often deprived from ad-
vanced systemic [9] or surgical [10] treatment approaches
due to comorbidities, supposed compliance, and financial
health policy aspects. Special issues include potentially
prolonged recovery periods, accumulated comorbidities, and
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prolongation of quality adjusted life years (QALYs) versus
disability-adjusted life years (DALYs). Clinical tools like the
ASA score allow estimation of the patient’s individual condi-
tion independent of chronological age [1].
Mortality is rather determined by the number of comorbid-
ities than by patient age alone [11]. In fact however, patients
aged 75 years have a mean of five comorbidities at the time
colorectal cancer is diagnosed [1]. The most relevant comor-
bidities for surgery are cardiovascular and pulmonary dis-
eases, tumor anemia, and liver or kidney disorders, which
are common in elderly patients [1–3]. Furthermore, neurolog-
ical or psychological disorders and polypharmacy are often
prevalent in aged patients [2]. Treatment-related toxicity can
occur by differences in the absorption, distribution, metabo-
lism and excretion of drugs [4, 5]. While elderly patients in
general are considered to have the same benefit from adjuvant
chemotherapy as younger individuals, data from the linked
Surveillance, Epidemiology and End Results (SEER)/Medi-
care database indicate that adjuvant chemotherapy does not
substantially improve overall survival in patients over the age
of 65 with stage II colon cancer [12].
The only curative treatment option for colorectal cancer
remains surgery [6, 10]. Previous studies suggest differences
between younger and older patients with colorectal cancer
regarding tumor stage, differentiation, and survival [12, 13].
Thus, the indication for colorectal cancer surgery in the elderly
is a matter of debate [10]. The question remains whether those
patients profit or may even be harmed by extensive surgery
[3]. Most prospective clinical trials do not enroll older per-
sons. If they do, individuals are likely to be comorbidity-free,
and therefore represent a highly selected group [4, 11]. The
aim of this study was to investigate whether age allows
stratification into different risk groups. Clinical and survival
differences of old versus young patients who all underwent




All patients undergoing surgery for colorectal cancer between
2007 and 2012 at the Department of Surgery, Klinikum rechts
der Isar, Technische Universität München, Munich, Germany,
were prospectively documented in a database. The last date of
inclusion and follow-up was May 2013. The Institutional
Review Board approved prospective data collection and ret-
rospective review of the patient charts for this project. Anal-
ysis was conducted on an anonymized data set. Documented
data include preoperative performance status, tumor staging
and multimodal treatment, details of the surgical procedures,
occurrence of complications, postoperative histopathology,
application of adjuvant or palliative treatment, and follow-up
(date of last visit, date and site of tumor recurrence, date of
tumor-related or unrelated death, tumor-specific and recur-
rence free survival). After discharge of the initial hospitaliza-
tion, patients are scheduled for periodic follow-up at the
interdisciplinary ambulatory tumor center of the clinic or
outside the hospital according to the recommendations of the
German Cancer Society [7]. The recommendations include
regular physical examination, blood analysis, abdomen ultra-
sonography or computed tomography, chest radiography, and
colonoscopy. Information from patients followed extramural
is obtained by periodic contacting the responsible general
practitioners, gastroenterologists, or patients themselves.
Statistical analysis
When applicable, age was calculated continuously for com-
paring young versus elderly patients in order to provide the
highest statistical power. For dichotomous group compari-
sons, all 569 patients were divided into young (<75 years;
n=410) and elderly (≥75 years; n=159). Statistical testing was
performed using IBM® SPSS® statics Version 19 (SPSS Inc.,
IBM Corporation Software Group, Somers, NY, USA). The
distribution of nominal or ordinal scaled variables was com-
pared by Pearson’s chi-square test. Cardinal variables were
tested for normal distribution by visualization on a histogram
and by the Kolmogorov–Smirnov test. For comparison of
independent groups, the t test was used for normal distribution
and the Mann–Whitney U test for non-normal distribution.
All tests were performed two-sided, and p values less than
0.05 were considered to be statistically significant. No correc-
tion of p values was applied to adjust for multiple test issue.
However, the results of all conducted statistical tests are
thoroughly reported, so that an informal adjustment of p values
can be performed while reviewing the data [14].
Time-dependent survival probabilities were estimated with
the Kaplan–Meier method and the log-rank test was used to
compare subgroups. To investigate the effect on survival of
multivariable relationships among covariates, Cox proportion-
al hazard models were used. Survival times as well as esti-
mated hazard ratios (HRs) were calculated and reported in
95 % confidence intervals (CIs). Performed statistical tests are
indicated if not self-explanatory.
Results
Patient cohort
Between 2007 and 2012, a total of 636 patients underwent
surgery for colorectal cancer at our institution. The median
follow-up was 22 months (range 1–60 months). In 28 cases,
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surgery was performed due to recurrence of previous disease.
In 39 cases, in situ carcinoma (Tis, UICC 0; n=16) was
diagnosed or pathological analysis revealed rare histological
entities (adenosquamous carcinoma, gastro-intestinal stroma
tumors, neuroendocrine tumor/carcinoma, n=23). Those pa-
tients were excluded, leaving finally 569 patients for the
analysis.
Of all 569 included patients, there were more men (n=342,
60 %) than women (n=227, 40 %). The mean age was 66±
13 years (standard deviation). The median age was 68 years,
with the youngest patient being 28 years and the oldest patient
being 96 years (Fig. 1). Characteristics of the patient cohort
are described in Table 1. The tumor was located in the colon in
65 % (n=371) and in the rectum in 35 % (n=198). Surgical
procedures included right hemicolectomy (n=162), resection
of the transverse colon (n=5), left hemicolectomy (n=58),
resection of the sigmoid (n=81), (sub) total colectomy (n=
25), anterior rectal resection (n=182), Hartmann’s procedure
(n=22), abdomino-perineal resection (n=29), and transanal
endoscopic microsurgery (n=5). The UICC/AJCC tumor
stage was stage I in 25 % (n=143), stage II in 26 % (n=
149), stage III in 28 % (n=158), and stage IV in 21 % (n=
119).
Intraoperative morbidity was 4 % (n=22), including respi-
ratory failure, hemorrhage, or iatrogenic injury of adjacent
organs. Postoperative surgical complications occurred in
39 % of all patients (n=222), including minor morbidity like
impaired wound healing (n=134) and postoperative intestinal
hypomotility or voiding disorder (n=34). The non-surgical
morbidity was 25 % (n=142), mainly caused by pneumonia
and urinary tract infections. Anastomotic leakage occurred in
4 % (n=23), diagnosed by the drainage fluid, CT scan or
surgical re-intervention. The perioperative 30-day mortality
was 3 % (n=19), mainly caused by a rapid progress of
metastasis with consecutive liver failure or by disseminating
infection and septic shock.
The median length of hospital stay was 21 days (range 3–
92 days). A total of 374 patients (66%) were monitored on the
intensive care unit postoperatively, with a median stay of
2 days (range 1–47 days). During surgery, packed red blood
cells were transfused in 19 % of the patients (109 of all 569
patients). The tumor-specific 2-year survival for all patients
was 86±2 %.
Differences between younger and elderly patients
at presentation
All 569 patients were divided into younger (<75 years; n=
410) and elderly (≥75 years; n=159). Characteristics of these
two groups are depicted in Table 1. There were no significant
differences between younger and elderly patients regarding
preoperative bowel obstruction by the tumor (p=0.99) or the
rate of emergency surgery (p=0.61). However, elderly pa-
tients were more likely to have one or more comorbidities
(85 % vs. 56 %, p<0.001, chi-square) and had higher ASA
scores (ASA III/IV: 52% vs. 20%, p<0.001, chi-square). The
mean age of patients with ASA I was 54 years (95 % CI 51–
58), for ASA II 65 years (63–66), for ASA III 73 years (72–
75), and for ASA IV 78 years (70–85; p<0.001 for concordant
increase of age and ASA upon one-way ANOVA).
Perioperative differences between younger and elderly
patients
There were no significant differences between younger and
elderly patients regarding the frequency of multivisceral re-
sections (p=0.37) or the number of intraoperatively adminis-
tered packed red blood cells (p=0.07; Table 1). However,
more proximal tumors occurred within the elderly (cecum to
splenic flexure, 42 % vs. 28 %, p<0.001). There were no
significant differences in the distribution of T stage (p=0.06),
N stage (p=0.17), tumor grading (p=0.14), mucinous or sig-
net ring cell tumor subtype (p=0.42), lymphovascular inva-
sion (p=0.21), angioinvasion (p=0.87), or perineural invasion
(p=0.57; Table 1). Interestingly, elderly patients were less
likely to have synchronous distant organ metastasis (14 %
vs. 23 %, p=0.02), and thus had lower UICC/AJCC tumor
stages (p=0.004). Of note, in spite of the lower tumor stages in
elderly patients, the rate of R0 resections did not differ signif-
icantly between the two age groups (p=0.42 for the primary
colorectal tumor site and p=0.22 for systemic R0 resections).
Elderly patients had a longer stay in the hospital (mean 24±
12 vs. 20±13 days, p=0.002, t test). Postoperatively, they
were more often monitored on the intensive care unit (77 %
vs. 62 %, p<0.001). When transferred to the intensive care
unit, the stay was longer for elderly patients (mean 4±7 vs. 2±









Fig. 1 Age distribution of the patient cohort
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Table 1 Clinical and histopathological characteristics of the patient cohort
Age <75 years n=410 (%) Age ≥75 years n=159 (%) All patients n=569 (%) p
Gender
Male 259 (63) 83 (52) 342 (60) 0.02
Female 151 (37) 76 (48) 227 (40)
Tumor location
Coecum— splenic flexure 114 (28) 67 (42) 181(32) <0.001
Descending colon— sigmoid 137 (55) 55 (35) 192 (34)
Rectum 159 (37) 37 (23) 196 (34)
ASA
I 51 (12) 3 (2) 54 (10) <0.001
II 254 (62) 66 (42) 320 (56)
III 77 (19) 77 (48) 154 (27)
IV 5 (1) 6 (4) 11 (2)
missing 23 (6) 7 (4) 30 (5)
Comorbidities
No 179 (44) 24 (15) 203 (36) <0.001
Yes 231 (56) 135 (85) 336 (64)
Tumor obstrucion
No 318 (78) 124 (78) 442 (78) 0.99
Yes 21 (5) 8 (5) 29 (5)
Missing 71 (17) 27 (17) 98 (17)
Presurgical treatment
No 313 (76) 143 (90) 456 (80) <0.001
Yes 97 (24) 16 (10) 113 (20)
Surgery
Elective 384 (94) 147 (92) 531 (93) 0.61
Emergency 26 (6) 12 (8) 38 (7)
Surgery: PRBC (mean±SD) 0.5±1 1±4 0.7±2 0.07
Surgery: duration (min, mean±SD) 220±90 199±88 214±90 0.02
Multivisceral surgery
No 335 (82) 135 (85) 47 (83) 0.37
Yes 75 (18) 24 (15) 99 (17)
Intraoperative complications
No 397 (97) 150 (94) 547 (96) 0.17
Yes 13 (3) 9 (6) 22 (4)
General complications
No 319 (78) 108 (68) 427 (75) 0.02
Yes 91 (22) 51 (32) 142 (25)
Surgical complications
No 250 (61) 9 (61) 347 (61) 0.99
Yes 160 (39) 62 (39) 222 (39)
Anastomotic leakage
No 394 (96) 15 (96) 546 (96) 0.79
Yes 16 (4) 7 (4) 23 (4)
Length of hosp. stay (days, mean±SD) 20±13 24±12 21±12 0.002
Length of ICU stay (days, mean±SD) 2±3 4±7 2±5 0.003
Perioperative mortality
No 11 (3) 8 (5) 19 (3) 0.03
Yes 399 (97) 151 (95) 550 (97)
Postsurgical treatment
No 233 (57) 120 (76) 353 (62) <0.001
Chemotherapy 170 (41) 37 (23) 207 (36)
(Chemo-)radiation 7 (2) 2 (1) 9 (2)
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did not increase significantly in elderly patients (6 % vs. 3 %,
p=0.17), but the mean age for patients developing
intraoperative complications was significantly higher (73 vs.
66 years, p=0.02, t test). There was no increase of surgical
Table 1 (continued)
Age <75 years n=410 (%) Age ≥75 years n=159 (%) All patients n=569 (%) p
T
T1 61 (15) 12 (8) 73 (13) 0.06
T2 72 (18) 26 (16) 98 (17)
T3 203 (49) 95 (60) 298 (52)
T4 74 (18) 26 (16) 100 (18)
N
N0 222 (54) 100 (63) 322 (57) 0.17
N1 107 (26) 34 (21) 141 (25)
N2 81 (20) 25 (16) 106 (19)
Lymph nodes resected (mean±SD) 19±9 18±7 18±9 0.16
Lymph nodes positive (mean±SD) 3±5 2±6 2±5 0.47
Lymph node ratio 0.121 0.104 0.117 0.38
M
M0 314 (77) 136 (86) 450 (79) 0.02
M1 96 (23) 23 (14) 119 (21)
Stage (UICC/AJCC)
I 109 (27) 34 (21) 143 (25) 0.004
II 92 (22) 57 (36) 149 (26)
III 113 (28) 45 (28) 158 (28)
IV 96 (23) 23 (15) 119 (21)
Histological grading
G1/2 273 (67) 117 (74) 390 (68) 0.14
G3/4 132 (32) 42 (26) 174 (31)
Missing 5 (1) 0 5 (1)
Lymphatic invasion
L0 310 (76) 128 (81) 438 (77) 0.21
L1 100 (24) 31 (19) 131 (23)
Angioinvasion
V0 359 (88) 140 (88) 499 (88) 0.87
V1 51 (12) 19 (12) 70 (12)
Perineural invasion
Pn0 390 (95) 153 (96) 546 (95) 0.57
Pn1 20 (5) 6 (4) 26 (5)
Tumor type
Adenocarcinoma 364 (89) 144 (91) 508 (89) 0.42
Mucinous adenocarcinoma 44 (11) 13 (8) 57 (10)
Signet ring cell carcinoma 2 (0.5) 2 (1) 4 (1)
R (local)
R0 381 (93) 151 (95) 532 (93) 0.42
R1 17 (4) 3 (2) 20 (4)
R2 0 0 0
RX 12 (3) 5 (3) 17 (3)
R (systemic)
R0 336 (82) 141 (89) 477 (84) 0.22
R1 19 (5) 3 (2) 22 (4)
R2 42 (10) 11 (7) 53 (9)
RX 13 (3) 4 (2) 17 (3)
PRBC Packed red blood cells, SD Standard deviation, ICU Intensive care unit
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morbidity by age. Elderly patients had the same risk of surgi-
cal complications (39 %, p=0.99; Table 1), without relevant
changes in the composition. Further, anastomotic leakage
occurred in 4 % in both ages groups (p=0.79). The mean
age for patients without postoperative surgical complications
was 67 years, the mean age for patients with postoperative
surgical complications was 66 years (p=0.74, t test). In con-
trast to intraoperative and surgical complications, elderly pa-
tients developed more general complications like pneumonia
and urinary tract infections (32 % vs. 22 %, p=0.02, chi-
square). The mean age for patients without general complica-
tions was 66 years, for patients with general complications
69 years (p=0.004, t test). High ASA scores were associated
with higher levels of general morbidity (p<0.001), but not
with intraoperative (p=0.28) or surgical (p=0.28) morbidity,
nor with anastomotic leakage (p=0.46). Perioperative mortal-
ity within the first 30 days after surgery was significantly
elevated in the elderly patient group (5 %, n=8) compared to
the younger group (3 %, n=11; p=0.03).
Differences between younger and elderly patients
during follow-up
Accompanied by lower tumor stages in elderly patients, the
rate of systemic treatment was reduced in this group, both
preoperatively (10 % vs. 24 %, p<0.001) and postoperatively
(24 % vs. 43 %, p<0.001). However, no significant differ-
ences were detected for the rate of tumor recurrence (log rank,
young vs. elderly, p=0.11) and tumor-specific survival (p=
0.90; Fig. 2). The increase of patient age by 1 year led to a
non-significant increase of the risk of tumor-specific death by
1 % (HR 1.01, 95 % CI 0.99–1.03, p=0.21). The tumor-
specific 2-year survival for all stages was 87±2 % for the
young and 83±4 % for the elderly patients (p=0.90). In
particular, for stages I, II, III, and IV, the tumor-specific
survival was 94±3 %, 98±2 %, 92±3 %, and 61±6 %,
respectively, for the younger patients (Fig. 3). For the elderly
patients, it was 100 %, 81±7 %, 83±7 %, and 61±7 %,
respectively. Accompanied by small group sizes, there was
only a significantly reduced survival for elderly patients in
UICC/AJCC stage II (p=0.73 for stage I, p=0.02 for stage II,
p=0.17 for stage III, p=0.96 for stage IV). Finally, age was no
independent prognostic factor upon multivariable analysis for
tumor-specific survival (Table 2).
Discussion
Individually tailored treatment regimens and patient age
Multiple treatment options for patients with colorectal cancer
exist. Patient age alone does not provide relevant information,
rather comprehensive physical assessment is crucial. Biolog-
ically younger patients of the same chronological age as
prematurely aged patients may require different treatment
approaches [1]. The decision whether a patient will profit most
from radical surgery or from non-oncological limited proce-
dures in terms of expectancy and quality of life should be
made on an individual basis in a multidisciplinary tumor
conference. If correctly assessed and treated, the majority of
patients older than 80 years maintain social independence
after surgery [15]. Although it is difficult to predict the indi-
vidual outcome of aged multimorbid patients [10], this study
shows that oncological long-term results do not differ between
age groups.
Here, young versus elderly patients, who all underwent
oncological resection for colorectal cancer, were compared.
The aim was to reveal relevant differences for elderly patients,
who tend to have higher comorbidities. By the retrospective
setting, the study presents relevant findings which may not be
obtained by prospective trials with strict inclusion criteria
regarding comorbidity or age. Only patients undergoing cura-
tive or palliative resection of their primary tumor were includ-
ed in this study. Thus, multimorbid patients who did not
undergo surgery were missed. However, inclusion of solely
Patients at risk
Young 410 254 167 96 46 0
Elderly 159 92 51 28 8 0
Tumor specific survival











Young 410 201 129 74 35 0
Elderly 159 83 45 24 7 0
Recurrence free survival










Fig. 2 No significant difference
in tumor-specific survival and
recurrence free survival between
young and elderly patients was
observed. Apparently, overall
survival was reduced for elderly
patients (p=0.03; graph not
shown)
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surgical patients allowed the comprehensive analysis of his-
topathological data, like TNM status and tumor grading.
Young and elderly patients display specific baseline
characteristics
In a review including 34,194 patients from 28 original studies,
characteristics of young versus old patients with colorectal
cancer with and without tumor resection were analyzed
[10]. Preexisting comorbidities were more frequent in
the elderly, but it was methodically impossible to per-
form a meta-analysis due to different definitions and
morbidity assessments. Furthermore, complications upon
treatment were significantly higher in elderly patients,
mainly including respiratory, cardiovascular, cerebrovas-
cular, or thromboembolic morbidity [10]. As found in
our study, higher rates of comorbidities and higher ASA
scores required a longer hospital stay for elderly pa-
tients for the preoperative assessment and postoperative
surveillance, as well as longer postsurgical intensive
care monitoring. However, an increased number of gen-
eral complications in elderly patients may also have led
to a prolonged hospital and ICU stay [3, 10].
Whether increasing patient age is associated with limited or
more advanced tumor stages has been discussed controver-
sially [4, 10, 13]. Some authors describe higher tumor stages
for young patients [13], as found in our study. Possible expla-
nations are increased symptom tolerance and less aggressive
screening or surveillance among younger people, leading to
higher stages at diagnosis. Other authors propagate higher
tumor stages for elderly patients, maybe due to masked signs
of malignancies and altered presentation of signs and symp-
toms of cancer in the elderly [4, 10]. Tumor genetics could
explain interobserver and interindividual differences [5, 16].
Colorectal cancers of the sporadic microsatellite instability
pathway are often associated with advanced patient age, prox-
imal tumor localization, early tumor stages, mucinous or
signet ring cell subtype, and poor differentiation but favorable
prognosis [13, 17, 18]. This may lead to the reduced rate of
synchronous metastasis and the higher rate of right sided
Patients at risk
I 109 70 50 30 14 0
II 92 51 39 25 14 0
III 113 80 49 27 12 0
IV 96 53 29 14 6 0
Younger: tumor specific survival














I 34 34 34 10 3 0
II 57 34 21 13 2 0
III 45 28 13 4 3 0
IV 23 9 2 1 0 0
Elderly: tumor specific survival













Fig. 3 Tumor-specific survival
for younger and elderly patients,
depending on tumor stage. While
the survival was significantly
reduced with progressive tumor
stages (I, II, III, and IV), a
significant difference between
younger and elderly patients was
only detectable in stage II (see
text)
Table 2 Multivariable analysis of risk factors for tumor-specific survival
p HR 95 % CI
Lower Upper
Young 1
vs. elderly 0.79 1.9 0.58 2.05
Men 1
vs. women 0.03 1.72 1.06 2.79
Colon 1
vs. rectum 0.86 0.95 0.56 1.62
ASA I 1
vs. ASA II 0.14 1.98 0.80 4.89
vs. ASA III 0.002 5.01 1.85 13.6
vs. ASA IV <0.001 49.2 10.8 224
Stage I 1
vs. stage II 0.40 1.56 0.59 4.34
vs. stage III 0.07 2.48 0.94 6.53
vs. stage IV 0.004 5.06 1.68 15.2
G1/2 1
vs. G3/4 0.001 2.32 1.39 3.90
R0 1
vs. R1 0.02 3.65 1.26 10.6
vs. R2 <0.001 4.76 2.07 10.9
Known risk factors like TNM stage and resection status (R) were included
in order to test for the independent prognostic capability of patient age
(young, 74 years or younger vs. elderly, 75 years or older). Although the
hazard ratio (HR) was 1.9-fold elevated for elderly patients, patient age
did not turn out to be an independent prognostic factor (p=0.79). In
contrast, gender, ASA III/IV, stage III/IV, grading (G), and resection
status were independent prognostic factors
95 % CI 95 % confidence interval
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tumors that has been identified in the elderly patients of our
cohort. Shortening of telomeric length and metabolic changes
during cell senescence may play a further not yet identified
role [5]. However, neither in this nor in a previous study [18],
we identified a correlation of the histological tumor subtype
and patient age.
Concordant to our results, the median absolute frequency
of postoperative mortality in the studies included in the review
mentioned before [10] was 3 % in the less than 65 years age
group, 6 % for 65–74 years, 9 % for 75–84 years, and 19 % in
the 85 years and above age group. Contradictory to our results,
the proportion of patients undergoing emergency surgery was
described more than twice as high in the 85 years and above
group than in the less than 65 years group [10]. Survival of
emergency cases has been shown to be poorer than in those
who undergo elective surgery as a result of a higher perioper-
ative mortality rate after emergency surgery (p<0.001 for our
cohort, data not shown) [3, 10, 13]. Differences between
studies may be explained, at least in part, by the considerably
lower number of patients in our analysis.
Young and elderly patients do not differ in long-term outcome
In concordance with the literature [10], we did not find a
significant difference for anastomotic leakage between young
and elderly patients. The finding that curative resections de-
crease with advancing age was not confirmed in our study,
however, could be attributed to age-related differences in
seeking medical advice, recognition of symptoms, or
primary-care referral patterns [10]. In a prospective study of
57 patients aged 80 years or older and undergoing resection of
their primary colorectal carcinoma, Kruschewski et al. [3]
showed proof that oncological resections should not be denied
to older patients. Based on the fact that age-corrected survival
of elderly and younger patients is comparable, and in concor-
dance with our study, lethality in elderly patients was identi-
fied to be mainly caused by general complications. None of
the 57 patients described by Kruschewski et al. [3] died
because of surgical morbidity. Thus, limited resections for
fear of an otherwise elevated risk of anastomotic leakage
cannot be justified [3]. Similarly, O'Connor et al. [12] found
that 28 patients aged 40 years and younger had no differences
of survival compared to 190 patients aged over 40 years,
although younger patients had higher rates of mucinous ade-
nocarcinoma. In contrast, Chou et al. [13] described poorer
disease-free survival for elderly patients. However, the latter
study raises some questions as older patients with obviously
higher chance of dying due to any reason had reduced disease
free survival, but not overall survival. The broad literature
does not confirm relevant differences of cancer-specific sur-
vival between older and younger patients who underwent
curative surgery [3, 10]. In a review, which is in line with
our data, 2-year tumor-specific survival rates for patients <65,
65–74, 75–85, and ≥85 years were 89 %, 85 %, 85 %, and
78 %, respectively [10].
Conclusion
Oncological long-term outcome of surgery for colorectal can-
cer does not differ significantly between elderly and younger
patients. Neither intraoperative, nor surgical complications
seem to increase with advanced age. However, elderly patients
have significantly higher comorbidity. Accurate monitoring is
important due to the elevated rate of general morbidity and
perioperative mortality in this subgroup.
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